Understanding Vitiligo: Misconception & Myth

Vitiligo is a skin disorder which causes the loss of pigment - melanin - in the skin.

Though it affects around 45 million people worldwide, common understanding of vitiligo has been clouded by misconceptions, leading to the stigmatization of those affected by the disease.

Modern medical understanding easily corrects much of this misunderstanding.

In presenting this information we hope to facilitate a better common understanding of vitiligo, and to help people gain an insight into this distressing disorder.

Produced March 2012. Learn more about Clinuvel's vitiligo program.

Quote references:

Vitiligo Support International: http://www.vitiligosupport.org/vitiligo/

Kaimal & Thappa, (2010). "Diet in Dermatology". IJDVL 76(2):103-115. Available online: http://www.ijdvl.com/article.asp?issn=0378-6323;year=2010;volume=76;issue=2;spage=103;epage=115;aulast=Kaimal

Gauthier & Benzekir in Picardo & Taieb (2010). "Vitiligo". Springer (1st edition).

Image references:

Our thanks to Hedvig Lindahl and Lee Thomas

Clinuvel Blog Posts

Today, February 28, marks Rare Disease Day: an annual event to help highlight the effects of rare diseases on individuals, families and the...

Read More

We've just released the first results from our vitiligo program which you can view online here. Following their release, we expect a number...

Read More

I find vitiligo to be a fascinating, yet devastating disorder: almost overnight, patients see their skin colour erode and their identity...

Read More

Clinuvel Webcasts

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Clinuvel Spotlight

The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE®) an...

Read more